![]() |
Volumn 12, Issue 1, 2000, Pages 30-35
|
Clinical studies of new "biologic" approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIBODY CONJUGATE;
BISMUTH;
CD33 ANTIBODY;
CD33 ANTIBODY I 131;
CD33 ANTIGEN;
CD45 ANTIBODY;
CD45 ANTIBODY I 131;
CD45 ANTIGEN;
CYCLOPHOSPHAMIDE;
CYTARABINE;
CYTOTOXIC AGENT;
GEMTUZUMAB OZOGAMICIN;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;
GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY;
HYBRID PROTEIN;
IDARUBICIN;
IMMUNOTOXIN;
IODINE 131;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY HUM 195;
MONOCLONAL ANTIBODY HUM 195 BI 213;
RADIOISOTOPE;
RETINOIC ACID;
UNCLASSIFIED DRUG;
ACUTE GRANULOCYTIC LEUKEMIA;
ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY;
BLOOD TOXICITY;
CLINICAL TRIAL;
DRUG DELIVERY SYSTEM;
DRUG EFFICACY;
DRUG TOLERABILITY;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
IMMUNOMODULATION;
ISOTOPE LABELING;
PRIORITY JOURNAL;
REVIEW;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD;
ANTIGENS, CD45;
ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC;
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR;
HUMANS;
IMMUNOCONJUGATES;
LEUKEMIA, NONLYMPHOCYTIC, ACUTE;
RECOMBINANT FUSION PROTEINS;
|
EID: 0034519298
PISSN: 10408746
EISSN: None
Source Type: Journal
DOI: 10.1097/00001622-200001000-00005 Document Type: Review |
Times cited : (21)
|
References (25)
|